Ota’s nevus is a congenital benign oculodermal melanocytosis as a macular hyperpigmentation on the face. The color of lesion is mostly blotchy gray to blue or blue. Ota’s nevus can cause emotional and psychological distress becausethe face can be a disfigurement, so appropriate treatment is necessary. However treating the Ota’s nevus without side effects such as purpura, crust, postinflammatory hyperpigmentation and scarring is extremely difficult. Therefore, the authors introduce a new treatment using Dr. Hoon Hur’s Golden Parameter with a high fluence 1064 nm Q-switched Nd: YAG laser that can effectively treat Ota's nevus without side effects and recurrences.
Café-au-lait macules (CALMs) are light to dark brown macules or patches of increased melanin concentration found along the dermoepidermal junction. Although many attempts to treat CALMs using various kinds of laser/light-based devices have been reported, CALMs remain refractory thereto with high recurrence rates. In this case series, we describe four patients with idiopathic CALMs that were effectively and safely treated with a non-ablative, high-fluenced, Q-switched (QS), 1064-nm neodymium: yttrium aluminum garnet (Nd:YAG) laser. The typical laser parameters for treating CALMs, including a spot size of 7–7.5 mm, a fluence of 2.4–2.5 J/cm2, and one to two passes until the appearance of mild erythema, but not petechiae, were utilized in this study over 12–24 treatment sessions at 2-week intervals. We suggest that high-fluenced QS 1064-nm Nd:YAG laser treatment can be used as an effective and alternative treatment modality for CALMs with minimal risk of side effects.
Café Au lait spot (CALS), partial unilateral lentiginosis (PUL) and Becker’s nevus (BN) are recalcitrant pigmentary skin diseases. Histopathologically, since nevus cell does not exist in CALS, PUL and BN, and these lesions of CALS, PUL and BN are not changed into malignant lesion, therefore CALS, PUL and BN are the benign pigmentary skin diseases. That said, treatment is not necessary for CALS, PUL and BN except cosmetic concerns. However, treatment for CALS, PUL and BN without side effects such as postinflammatory hyperpigmentation (PIH), scars and recurrences cannot be found in any literature yet. Therefore, the authors introduce the treatment of CALS, PUL and BN using a high fluence 1064-nm Q-switched Nd: YAG laser without the side effects or recurrences.
A congenital melanocytic nevus (CMN) is present at birth in approximately 1% of newborn infants. Treating CMN with a single laser without complications is very difficult because of the deep-penetrating nature of the nevus cells in this lesion. A 51-year-old female patient presented with a single 8 cm x 14 cm sized dark brown to black plaque with scar on the left side of face. She received 10 treatment sessions of an intense pulsed light therapy and then 20 treatment sessions of Dr. Hoon Hur’s Golden Parameter Therapy with a high fluence 1064 nm Q-switched Nd: YAG laser. Complete clearance of CMN was obtained and no side effects were observed. This result has been maintained for up to 24 months’ follow-up. We suggest that this new combination treatment will be a good option for treating CMN with minimal scarring.
Café au lait spot (CALS) is a light or dark brown spot that has various sizes (diameter of 0.5cm-30cm). Solitary or multiple lesions may occur on any parts of body except palms and soles at birth or in infancy. Histopathologically, since nevus cell does not exist in CALS and CALS is not changed into malignant lesion, therefore CALS is a benign pigmented disease [1,2]. That said, treatment is not necessary for CALS except cosmetic concerns [1,2-5]. However, treatment for CALS without side effects such as postinflammatory hyperpigmentation (PIH), scars and recurrences cannot be found in any literature yet. Therefore, the author introduces Dr. Hoon Hur’s Golden Parameter Therapy (GPT), using a 1064nm Q-switched Nd:YAG laser without the side effects or recurrences.
Partial unilateral lentiginosis (PUL) is a pigmentation disorder characterized by multiple lentigines covering the normal skin with a unilateral, segmented pattern that stops at the midline. There has only been a few successful PUL treatments reported in the literature, and an ideal therapeutic method has not yet been identified. We report a case of facial PUL that was successfully treated with a 532-nm Q-switched neodymium-ser with subsequent low-fluence 1,064-nm QS Nd:YAG laser treatment. The patient did not experience recurrence until 3 years after the treatment. This appears to be a promising therapeutic approach for PUL. Additional research should be conducted for further assessment of this method.
At 6 weeks after 3 sessions of laser treatment, all patients demonstrated clinical improvement. Erythema lesion counts decreased by 20.1% (versus baseline) after the first treatment (P = 0.004), by 32.7% after the second treatment, by 46.5% at 2 weeks after the third treatment and by 58.7% at the 6-week follow-up (all P < 0.001). Significant improvements were also noted in erythema indices (22.29 ± 2.4 to 17.51 ± 1.8) and mean post-acne erythema scores after the first treatment (both P < 0.001). The mean scores of independent physician assessments were 4.04 ± 0.9 in term of the improvement of post-acne erythema and 3.44 ± 0.9 in the improvement of scarring. In addition, we could observe a significant decrease in inflammatory acne lesion counts after two laser treatments with a decrease in mean lesion counts by 67% at the 6-week follow-up. Treatment was well-tolerated and adverse effects were limited to transient erythema and edema at treatment sites. Low-fluence 585 nm Q-switched Nd:YAG laser treatment is safe and effective for the treatment of post-acne erythema with minimal discomfort and quantifiable improvement in the appearance of early acne scarring and inflammatory acne.
One male and fifteen females, mean age of 43.4(range 32–64) years, completed the 29-week study. Bothlaser treated sides showed a significant improvement inMMASI evaluations after two treatments (22% improvement on the QS-Nd:YAG, 17% QSAL) and each follow-up visit 2 (36% QS-Nd:YAG; 44% QSAL), 12 (27% QS-Nd: YAG; and 24% QSAL), and 24 weeks (27% QS-Nd:YAG; and 19% QSAL) after the last treatment, but no significant difference was seen between study groups at any visit. There was also no significant difference in subject evaluation of improvement between both treatment sides at any visit. Both laser treated sides were tolerated well, and no serious adverse events were noted. Only one subject was taken out of the study due to development of postinflammatory hyperpigmentation bilaterally. Both low-fluence Q-switched Nd:YAG and low-fluence QSAL were equally effective at improving moderate to severe mixed-type facial melasma.
In the combination group, the partial MASI score has significantly decreased by 47% at 1 month after the treatment (p < .05) and 50% at 2 months after the last treatment (p < .01). At 1 month and 2 months after the treatment, the decrease in the partial MASI score of the combination group was significantly larger than that of the IPL only group (p < .05). In both groups, treatment with IPL-F and LF-QS-Nd:YAG laser was well tolerated. Our results suggest that the combination of the IPL-F with LF-QS-Nd:YAG laser may be an effective and safe modality for melasma F16patients.
The mean fluence was less in patients younger than 10 years (2.2 6 0.3 J/cm2) than in those older than 10 years (2.8 6 0.8 J/cm2) (p = .006). Patients who started their first treatment earlier required fewer treatment sessions to reach moderate, marked, and near total improvement (p < .05). By starting treatment early, low mean fluence was required to reach the end point in each session (p < .001). Post-treatment hyperpigmentation was observed in 1 patient.This treatment was clinically effective and safe for early nevus of Ota using a low-fluence Q-switched Nd:YAG laser.
Background: Exogenous ochronosis (EO), a disfi guring cutaneous complication of topical hydroquinone use, is diffi cult to treat. There are few reports of successful outcomes following treatment with different modalities. Objective: We assessed the results of treatment of EO with the Q-switched Nd:YAG laser. Material and methods: Patients with histologically-confi rmed EO were treated with the Q-witched Nd:YAG laser. Results and conclusion: Q-switched Nd:YAG laser treatment appears to be effective in reducing the dyschromia of EO.
The application of Q-switched Nd:YAG laser toning is well-known for gentle removal of superficial pigmentation without exacerbating further darkening. The copper bromide wavelength of 578 nm is normally used to treat melanin anomaly group lesions, whereas the 511 nm green line is more associated with vascular lesion treatment. We used both lines for hyperpigmented NACs because it has been suggested that interactions between the altered cutaneous vasculature and melanocytes may influence the epidermal hyperpigmentation via vascular endothelial growth factor (VEGF) and its receptor on the human melanocytes, and we believe that was demonstrated in the present study. Further study with larger populations is required to confirm the initialpromising results.
The low-fluence 1064-nm Q-switched neodymium:yttrium–aluminium–garnet (QSNY) laser is a widely used treatment for melasma in East Asia, although its mechanism of action is unclear. The aim of this study was to elucidate the mechanism of action of the QSNY laser. We performed a histopathological study on eight Korean women who had considerable improvement in their melasma lesions after a series of low-fluence QSNY laser treatments. Compared with nonlesional skin, samples from melasma lesions showed increased reactivity in melanin (Fontana–Masson staining) and in melanogenesis-associated proteins, including a-melanocyte-stimulating hormone, tyrosinase, tyrosinase-related protein (TRP)-1, TRP–2, nerve growth factor and stem cell factor. After laser treatment, the melasma skin showed a decrease in the number of melanosomes and reduced expression of melanogenesis-associated proteins. Expression levels of the melanogenic proteins were reduced after laser treatment, although the number of melanocytes was unchanged even in hypopigmented areas. Based on these results, we believe that repeated application of low thermal energy via QSNY laser may result in damage to melanocytes and long-lasting hypopigmentation.
Mean mMASI score 4 weeks after the second treatment decreased significantly in both groups from base line. Based on overall clinical improvement, a greater number of patients scored as grade 3 and more in the combination group; no patients were scored as grade 4 in the laser-alone group. Oral TA may prove a safe and efficient treatment option for melasma in combination with low-fluence QSNY laser therapy.
The mean number of total treatment sessions was 17.1 (range 6–32). Among the 19 patients, 18 reached near total improvement, while one patient failed to reach near total improvement after 11 treatment sessions. The mean fluence of treatment was 2.5 J/cm2 (range 2.0–5.0 J/cm2). Five patients complained of delayed eyelid response. Post-therapy hyperpigmentation was observed in one patient. Low fluence 1064 nm Q-switched Nd:YAG laser is an effective modality for the treatment of nevus of Ota with a low incidence of side effects. It is an easy to perform treatment with low downtime.
As energy-based aesthetic devices grow increasingly sophisticated and effective for all skin types, practitioners worldwide can choose from solutions that combine several treatment modalities on a single platform. This has become a selling point with physicians who treat a variety of skin types. However, with more choices of systems treating multiple indications, it may be difficult to decide which new technologies are right for a particular practice and its patients. Luckily, one brand in this crowded field has consistently provided faster, safer treatments and better clinical outcomes while continuing to evolve and improve their technology.
Acne remains a problem for dermatologists worldwide, but persistent erythema after successful acne treatment can present an even greater problem. The aim of the present study was to clarify the efficacy of low-fluence 585 nm Q-switched Nd:YAG laser treatment (Gold Toning™) for persistent facial erythema after acne treatment. Twenty female patients participated in the study (ages from 21 to 31 yr) randomly divided into 2 groups of 10, the Control and Treatment groups. Both groups first underwent superficial chemical peeling and physical comedone extraction, then the Treatment group received a number of low-fluence Gold Toning sessions (Q-switched 585 nm, 5-10 ns, 5 mm spot, 0.25- 0.40 J/cm²). Objective assessment from the clinical photography and subjective patient assessment were performed at the 8-week follow-up. Both the subjective and objective assessments showed significant improvement for the Gold Toning-treated group. This minimally-invasive approach therefore offers good results for persistent erythema post-acne treatment, and a potential range of other conditions.
Fibroblast growth factor (FGF)-9 play an important role in wound healing. However, the effects of non-ablative laser treatment on the expression of FGF9 have not been fully investigated. Non-ablative 1,064-nm quasi-long pulsed and Q-switched Nd:YAG laser treatments were delivered to hairless mice with and without a carbon photoenhancer. For histological and immunohistochemical analyses, sections were stained with hematoxylin and eosin as well as FGF9 antibody. Significantly increased epidermal and dermal thickness was noted in mice treated with carbon photoenhancer-assisted quasi-long pulsed or Q-switched laser treatments compared to those treated without a carbon photoenhancer. Expression of FGF9 was observed in both the epidermis and dermis in all groups of mice during the healing process. Earlier and more pronounced expression of FGF9 was detected in mice treated with carbon photoenhancer-assisted quasi-long pulsed laser therapy. In addition, two peaks of pronounced FGF9 expression were observed, especially in mice that underwent carbon photoenhancerassisted 1,064-nm quasi-long pulsed Nd:YAG laser treatment. A carbon photoenhancer seems to enhance the effect of quasi-long pulsed and Q-switched Nd:YAG laser treatment. Also, expression of FGF9 may play an important role in the healing process after laser treatments and could contribute to histometric changes.
This laser treatment was rapid and effective for treating not only the inflammatory but also the noninflammatory acne lesions when compared with the control side. The histopathologic findings correlated well with the clinical acne grade and treatment response. This novel laser treatment appears to be safe and effective for acne treatment.
Low-fluence 1,064-nm QS Nd:YAG laser treatment for facial PUL in Koreans showedimprovement with no significant side effects. We recommend the low-fluence 1,064-nm QS Nd:YAG laseras a treatment option for facial PUL.
In recent years, laser toning has gained popularity for the treatment of melasma, and tyrosinase inhibitors are conventionally used to prevent recurrence after this treatment. The effectiveness of this treatment modality, however, is still questionable, and additional in vivo studies are needed to validate the method. In this study, we used adult zebrafi sh skin as an adult melanocyte regenerative system and examined the simulated human skin response to laser toning. Melanosomes regenerated after selective photothermolysis, and these organelles showed a bi-directional translocation pattern in accordance with the changes of intact melanosome patterns. Furthermore, a tyrosinase inhibitor, 1-phenyl-2-thiourea (PTU), completely blocked melanosome regeneration after laser irradiation, but this inhibitor failed to prevent melanosome regeneration after the medication was discontinued. Finally, arbutin and kojic acid, the commercially available tyrosinase inhibitors, slowed down but did not completely block melanosome regeneration. Based on these fi ndings, we describe the limitations of laser toning treatment of melasma and the combined use of tyrosinase inhibitors. We suggest that melanosomes in adult zebrafi sh skin can be utilized for studying melanosome regeneration response to laser irradiation and for developing a system to assess the comparative effi cacy of melanogenic regulatory compounds.
Three weeks after the final treatment, 75% of the subjects showed improvement with method 1 whereas 67% showed improvement with method 2. No adverse side effects were reported with either method. Although histological confirmation was not performed, we were able to prove both subjectively and objectively that the use of the combination of the micropulsed and Q-switched modes of the Nd:YAG laser was useful in reducing pore size, and that the photoenhancer improved the efficacy.
The procedure was well-tolerated. By the fourth treatment significant improvement was observed, and by the sixth treatment, better than 90% clearance of inflammatory lesions was achieved. At the 8-week follow-up after the last treatment, long-lasting improvements in the patient's acne were noted. Improvement was also noted in closed comedones and in the general skin condition, especially pores, sebum reduction, and the red spots seen after inflammatory acne. The patient was satisfied with the result. This new, minimally invasive technique as a stand-alone treatment gave very good clearance of inflammatory acne with minimal patient down time. Marked reduction in active acne was observed during treatments and at the 2-month follow-up visit. Further improvement could probably be achieved with other adjunctive therapeutic modalities.
After seven sessions of treatment, the patient's skin color returned to normal. A low-fluence Q-switched 1064-nm Nd:YAG laser provided safe and effective treatment for the skin discoloration associated with argyria.
Erythema ab igne (EAI) is a persistent reticular macular dermatosis caused by repetitive and prolonged thermal exposure under the threshold. It begins as a mottling caused by local hemostasis and becomes a reticulated erythema, leaving epidermal atrophy and pigmentation and rarely leads to skin ulcers or epithelial atypia. Recently, exposure to various kinds of heat sources, such as heated furniture, car heaters, or even laptop computers, has been reported to cause this condition. Because sometimes the pigmentation is long-lasting or permanent, topical treatments such as hydroquinone cream could be tried, but there has been no effective treatment for EAI. Here, we postulate that low fluenced 1,064-nm QS Nd-YAG laser treatment, so called, laser toning, can be a kind of option for the treatment of EAI. Erythema Ab Igne Successfully Treated Using 1,064-nm Q-switched Neodymium-Doped Yttrium Aluminum Garnet Laser with Low Fluence. Available from: https://www.researchgate.net/publication/51039946_Erythema_Ab_Igne_Successfully_Treated_Using_1064-nm_Q-switched_Neodymium-Doped_Yttrium_Aluminum_Garnet_Laser_with_Low_Fluence [accessed Sep 29, 2017].
Laser treatment using low fluence for melasma was previously introduced to overcome postinflammatory hypermelanosis after Q-switched laser therapy. However, research on the mechanism of this treatment is very limited. In this study, a collimated low fluence 1064 nm Q-switched Nd: YAG laser with a pulse width of <7 ns was applied using top-hat beam mode. The aim of this study was to investigate the mode of action of this laser treatment through electron microscopy. The effectiveness of this treatment was confirmed by clinical photos, melasma area and severity index and spectrophotometer. To understand the mode of action, the three-dimensional structure of melanocytes in the epidermis was analyzed using serial images acquired by a 3VIEW surface block face scanning electron microscope. In the epidermis, after laser treatment, fewer dendrites in the melanocytes were observed compared with pretreatment. In addition, ultrastructural changes in the melanosome were studied using transmission electron microscopy, which showed that laser treatment caused selective photothermolysis on Stage IV melanosome. Therefore, this treatment should be regarded as an effective method for treating melasma through subcellular-selective photothermolysis.
The dual toning technique using the 1064 nm Nd:YAG laser was safe and effective, and well-tolerated by all patents without anesthesia. Larger controlled studies are merited with more objective measurement techniques to confirm the results of this preliminary study.
The above study by Jeong and colleagues (Dermatol Surg 2010; 36: 909-918) answers the important question of how medical skin lightening agents should be used in combination with laser therapy for the treatment of melasma. The 13 subject split-face study evaluated the efficacy of an 8-week application of 4% hydroquinone, 0.05% tretinoin, and 0.01% fluocinolone acetonide combination cream before or after low-fluence 1,064-nm Qswitched neodymium-doped yttrium aluminum garnet (Nd:YAG) laser treatment. This design was employed to determine whether it is better to suppress pigment production in melasma patients before laser injury to the skin or address the postinflammatory hyperpigmentation component only by medical skin lightening therapy after the laser treatment. The study demonstrated that pretreatment with medical skin lightening was most effective. This may be due to several factors, which will be briefly explored. The triple combination cream used for medical skin lightening in this research contained hydroquinone to inhibit melanin production, tretinoin to enhance hydroquinone penetration and decrease melanosome transfer, and fluocinolone acetonide to minimize irritation. Hydroquinone, a phenolic compound chemically known as dihydroxybenzene, functions by inhibiting the enzymatic oxidation of tyrosine and phenol oxidases. It covalently binds to histidine or interacts with copper at the active site of tyrosinase. It also inhibits ribonucleic acid and deoxyribonucleic acid synthesis and may alter melanosome formation, selectively damaging melanocytes. These activities suppress the melanocyte metabolic processes, inducing agradual decrease of melanin pigment production, but hydroquinone is a highly unstable compound undergoing rapid oxidation when exposed to air, resulting in the melanocyte-toxic products p-benzoquinone and hydroxybenzoquinone, which can cause depigmentation. It is the safety concerns arising from oxidized hydroquinone that have led to the recent controversy regarding its use in the United States, Europe, and Asia. Hydroquinone remains the most effective topical pigment-lightening agent currently available, and combining it with a topical retinoid and corticosteroid heightens its efficacy. This research demonstrated that pretreatment with the cream combination was more efficacious probably because it takes time to shut down the melanin-producing machinery. If melanin production is decreased before skin laser injury, postinflammatory hyperpigmentation is reduced and the melasma improved. If the medical creamtreatment is used only after laser injury, the melanin-producing machinery is operating at full capacity, increasing chances for postinflammatory hyperpigmentation and slowing the visual improvement of the melasma.The findings of this research are valuable to the dermatologic surgeon who treats pigmentary disorders. Medical hyperpigmentation therapy of at least 8 weeks should precede laser treatment for melasma to achieve the optimal result.
The latest version of the SPECTRA series laser platform from Lutronic Corporation (Ilsan, Korea), is clinically proven to treat a wide variety of conditions from melasma to skin rejuvenation. Respected by thousands of satisfied clinicians worldwide, this new modality combines essential aesthetic wavelengths in one device, providing outstanding versatility for aesthetic physicians throughout Asia.
The pore size and sebum level significantly decreased with treatment on the treated side (right cheek and right half of nose) in both the micropulsed and Q-switched modes compared to the control side (p<0.05), but without any statistically significant difference between the modes. The micropulsed and Q-switched Nd:YAG laser treatments reduced pore size and sebum levels with more or less equal efficacy and with no adverse side effects.
Our study confirmed that low-fluence Q-switched Nd:YAG laser energy, laser toning, could selectively photothermolyse melanosomes without killing melanocytes. This might offer a good approach for melasma treatment while preventing postinflammatory hyperpigmentation after melanocyte destruction, which is especially common in Asians.
After 16 weeks, better results were seen in subjective assessments when laser treatment was used after 8 weeks of topical TC treatment than before usage of TC. There were no significant adverse effects with the laser treatments. Laser treatment after topical TC cream was found to be safer and more effective than the post-treatment use of topical agents.
Recently, a new approach to treatment of melasma using the low fluence Q-switched (QS) 1064 nm Nd:YAG laser has increasingly been performed successfully and published as “laser toning” in Asian countries. However, we found some confusion with regard to the concept, mechanism and safe parameters in recent papers on laser toning. They use various passes (e.g., 2-10) of different low fluences (e.g., 1.6-5.0 J/cm²) and different intervals in order to achieve the observational clinical effect. Due to these wide variations of parameters, the clinical efficacy and safety of this modality has provoked controversy. Over the past few years, a couple of studies have been conducted on the effects of laser toning, however, little is known about the mode of action based on scientific concepts. In our clinical, ultrastructural and zebra fish studies, we found an effective, reliable and safe approachusing the low fluence QS 1064 nm Nd:YAG laser in treatment of melasma.
Follow-up data collected 3 months after the final treatment revealed decreases in the mean score for the following lesion characteristics: pigmentation from 1.8 to 1.2; vascularity from 1.4 to 1.0; pliability from 3.0 to 2.0 and height from 2.3 to 1.8. The modified Vancouver General Hospital Burn Scar Assessment score decreased from 8.6 to 5.9 (P < 0.0001). Observed side-effects were a mild prickling sensation during treatment, and mild posttreatment erythema, both of which resolved within few hours.Our results demonstrate that QS Nd:YAG laser with low fluence may be used for the treatment of keloids and hypertrophic scars.
Background: A variety of treatment modalities have been used to reduce the size of enlarged facial pores without obvious success. Objectives: To assess and compare the effects of various parameters of a 1064 nm Nd:YAG laser in the treatment of enlarged facial pores. Methods: This was a prospective intra-individual left-right comparative study. A total of 40 individuals with enlarged facial pores were recruited for this study. Ten individuals were respectively treated on one half of the face with a quasi long-pulsed 1064 nm Nd:YAG laser (method 1), a Q-switched 1064 nm Nd:YAG laser (method 2), both quasi long-pulsed and Q-switched 1064 nm Nd:YAG lasers without carbon-suspended lotion (method 3), and both quasi long-pulsed and Q-switched 1064 nm Nd:YAG lasers with carbon-suspended lotion (method 4). The other half of the face was left untreated as a control. Five laser sessions were performed with a 3-week interval. The pore sizes were measured using an image analysis program and the sebum level was measured with a Sebumeter® before and after the treatments. Results: The pore size and sebum level decreased in all four methods on the treated side compared to the control (p 0.05). onclusions: Treatment with a 1064 nm Nd:YAG laser is an effective method for reducing pore size and sebum level.
After a 2-month follow-up, the improvements were rated objectively by the investigators and subjectively by the patients. The investigators and patients reported improvements in melasma compared to the base line. Combination therapy of using topical carbon suspension-assisted Nd:YAG laser and 633 nm LED therapy may offer a safe, non-ablative method to improve skin textures and treat melasma.
Traumatic tattoos are undesirable tattoos caused by different foreign bodies such as fireworks' particles, sand, metals, glass, gunpowder, asphalt, dust, or petroleum products embedded forcefully in the dermis. We report the case of a 54‐year‐old man who presented with sand and asphalt tattooing on his face following a bomb explosion 15 years ago. Q‐switched Nd:YAG laser at a wavelength of 1064 nm with a spot size of 4 mm and a fluence of 7.96 J/cm2 were applied to treat the patient. The patient tolerated the treatment very well. Most of the blue dots became whitened immediately after the procedure and remained almost clear after a 6‐month follow‐up.
The collimated low fluence Q-switched Nd：YAG Laser is effective in melasma treatment. This treatment method is a new concept that can be described as selective photothermolysis with minimal thermal damage and inflammation reaction to affected tissues by pigmentation. We consider this treatment method should be regarded as Minimized Selective Photothermolysis
The Q-switched Nd:YAG laser methodwith short pulse width and low energy used in this study demonstrated better treatment effects than other conventional treatment methods. This treatment method is a new concept that can be described as selective photothermolysis with minimal thermal damage and inflammation reaction to affected tissues by pigmentation. We consider this treatment method should be regarded as Minimized Selective Photothermolysis (MSP) that will provide a new effective treatment for melasma.
According to Dr. Kang, Spectra Laser Toning has now become the gold standard for the treatment of melasma. “I have treated many patients, all with very high satisfaction. The best part is that a patient can be treated in as little as ten minutes.” Treatments can also be combined with other complementary therapies to achieve multiple clinical advantages, “making Spectra Laser Toning ideal for epidermal and dermal melasma,
Traumatic tattoos are undesirable tattoos caused by different foreign bodies such as fireworks' particles, sand, metals, glass, gunpowder, asphalt, dust, or petroleum products embedded forcefully in the dermis. We report the case of a 54-year-old man who presented with sand and asphalt tattooing on his face following a bomb explosion 15 years ago. Q-switched Nd:YAG laser at a wavelength of 1064 nm with a spot size of 4 mm and a fluence of 7.96 J/cm(2) were applied to treat the patient. The patient tolerated the treatment very well. Most of the blue dots became whitened immediately after the procedure and remained almost clear after a 6-month follow-up.